Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241703 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2HRH3KDM4EMEN1MAPT | |
| SCHEMBL18773643 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2HRH3KDM4EKMT2ACHRM3 | |
| SCHEMBL14600743 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2HRH3KDM4EMEN1MAPT | |
| SCHEMBL10241157 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2HRH3KDM4ECHRM3 | |
| SCHEMBL70520 | 0.72 | HRH3 (0.44) | SMN1; SMN2HRH3KDM4EMEN1MAPT | |
| SCHEMBL15387018 | 0.70 | HRH3 (0.43) | SMN1; SMN2HRH3KDM4EMEN1MAPT | |
| SCHEMBL27880313 | 0.70 | HRH3 (0.43) | SMN1; SMN2HRH3CHRM3HSD11B1 | |
| SCHEMBL7903518 | 0.70 | HRH3 (0.43) | SMN1; SMN2HRH3CHRM3HSD11B1 | |
| SCHEMBL28784801 | 0.69 | SMN1; SMN2 (0.42) | SMN1; SMN2HRH3KDM4EMEN1MAPT | |
| SCHEMBL14565366 | 0.69 | SMN1; SMN2 (0.42) | SMN1; SMN2HRH3KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | SMN1; SMN2 18/4885HRH3 3631/4885KDM4E 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.